Mortality Measures in Prostate Cancer
Author Information
Author(s): C.M. Goodman, A.W.S. Ritchie, G.D. Chisholm
Primary Institution: University Department of SurgerylUrology, Western General Hospital, Edinburgh
Hypothesis
Different expressions of mortality in prostate cancer can lead to difficulty in comparing reported data.
Conclusion
The study shows that using expected and relative survival rates provides a valuable and objective assessment of disease-specific mortality in prostate cancer.
Supporting Evidence
- 57% of the patients in the study had died by September 1988.
- The overall probability of survival at 5 years was calculated to be 33.1%.
- 62% of deaths were attributed directly to prostate cancer or conditions arising from it.
- Relative survival rates varied with age, increasing from 41% in the 45-54 age group to 58% in the 75-84 age group.
- 90% of patients with biochemical evidence of progressing disease were certified as having died of prostate cancer.
Takeaway
This study looked at how different ways of measuring death from prostate cancer can make it hard to compare results. It found that some methods are better than others for understanding how many people die from the disease.
Methodology
The study analyzed survival data from 438 patients with histologically confirmed adenocarcinoma of the prostate using life table methods and expected survival calculations.
Potential Biases
The reliance on death certification data introduces potential bias due to inaccuracies in reporting causes of death.
Limitations
The study acknowledges discrepancies in death certification and the challenges of accurately attributing causes of death.
Participant Demographics
The mean age of participants was 72.5 years, with a range from 45.3 to 91.0 years.
Want to read the original?
Access the complete publication on the publisher's website